Keyword: HIV vaccine

With HIV rates in the U.S. holding steady, health officials are looking to drugmakers to help drive down infections. Now, Gilead is ready to chip in.

J&J’s commissioned film about the early days of the AIDS epidemic is set to attract a wider audience, thanks to a Verizon Media distribution deal.

The International AIDS Vaccine Initiative will use grant funding to develop a Lassa vaccine based on the VSV vector.

Inovio's HIV vaccine is in early-stage development, but the company reported immune responses induced by the shot that lasted at least six months.

Johnson & Johnson and partners on Thursday pushed their promising "mosaic" HIV vaccine candidate into efficacy testing.

After successfully shepherding a Zika vaccine candidate into the clinic before any other developer, Inovio Pharmaceuticals is amping up its efforts in HIV.

Seeking to deliver the “final nail in the coffin for HIV,” NIH scientists have kicked off a large clinical trial of a vaccine regimen this week in South Africa.

A team of scientists from Australia is making progress in developing a vaccine that protects the human “surfaces” most likely to encounter the virus first.

It’s another silver lining for drugmakers targeting HIV: Researchers have found promise in a combo of a Johnson & Johnson vaccine and a Gilead immune booster.

Seeking to address a top public health priority, China’s Yisheng Biopharma has teamed with The Scripps Research Institute (TSRI) to advance vaccine research against HIV.